本帖最后由 老马 于 2012-1-13 21:20 编辑 * B& W0 X8 x" |* `( p4 ?+ Z
( `/ x ]+ \& N: B# @! I
爱必妥和阿瓦斯丁的比较
. Q9 B- K+ ~8 ]1 ~. ]/ l
8 f L$ u4 n2 D r% A
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ {4 X! H3 X- d9 H \; I. }) [. ~
8 u) n' f" `. ~" F _& J, E
5 O0 l: K- X3 c- T7 I& c9 s
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/4 j) T) N6 J: K
==================================================
7 T! ?4 M# A7 R: A; s4 [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# `5 R5 a2 p% O% W' bPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. M4 _0 c) l& K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* s5 ^7 d# B [' d6 }! P; R7 }1 R# L
|
显身卡
